Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients

Kihyun Kim, Seok Jin Kim, Verena Voelter, Cheolwon Suh, Sung Soo Yoon, Je Jung Lee, Jae Yong Kwak, Hun Mo Ryoo, Yang Soo Kim, Joon Ho Moon, Seong Kyu Park, Sung Hyun Kim, Yeung Chul Mun, Jinseok Kim, Hyeon Seok Eom, Deog Yeon Jo, Hyun Jung Jun, Ki Hwan Kim, Jeong Ok Lee, Jae Hoon Lee & 1 others Chang Ki Min

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.

Original languageEnglish
Pages (from-to)113-121
Number of pages9
JournalAnnals of Hematology
Volume93
Issue number1
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Korea
Dexamethasone
Thalidomide
Platelet Count
North America
Multiple Myeloma
Leukocyte Count
Survival
Therapeutics
Anorexia
Constipation
Fatigue
lenalidomide
Creatinine
Blood Platelets
Multivariate Analysis
Population

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Kim, Kihyun ; Kim, Seok Jin ; Voelter, Verena ; Suh, Cheolwon ; Yoon, Sung Soo ; Lee, Je Jung ; Kwak, Jae Yong ; Ryoo, Hun Mo ; Kim, Yang Soo ; Moon, Joon Ho ; Park, Seong Kyu ; Kim, Sung Hyun ; Mun, Yeung Chul ; Kim, Jinseok ; Eom, Hyeon Seok ; Jo, Deog Yeon ; Jun, Hyun Jung ; Kim, Ki Hwan ; Lee, Jeong Ok ; Lee, Jae Hoon ; Min, Chang Ki. / Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients. In: Annals of Hematology. 2014 ; Vol. 93, No. 1. pp. 113-121.
@article{0e888708b20d4ecd9b73904742c6ec74,
title = "Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients",
abstract = "We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 {\%} with 15.4 {\%} of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.",
author = "Kihyun Kim and Kim, {Seok Jin} and Verena Voelter and Cheolwon Suh and Yoon, {Sung Soo} and Lee, {Je Jung} and Kwak, {Jae Yong} and Ryoo, {Hun Mo} and Kim, {Yang Soo} and Moon, {Joon Ho} and Park, {Seong Kyu} and Kim, {Sung Hyun} and Mun, {Yeung Chul} and Jinseok Kim and Eom, {Hyeon Seok} and Jo, {Deog Yeon} and Jun, {Hyun Jung} and Kim, {Ki Hwan} and Lee, {Jeong Ok} and Lee, {Jae Hoon} and Min, {Chang Ki}",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00277-013-1893-z",
language = "English",
volume = "93",
pages = "113--121",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "1",

}

Kim, K, Kim, SJ, Voelter, V, Suh, C, Yoon, SS, Lee, JJ, Kwak, JY, Ryoo, HM, Kim, YS, Moon, JH, Park, SK, Kim, SH, Mun, YC, Kim, J, Eom, HS, Jo, DY, Jun, HJ, Kim, KH, Lee, JO, Lee, JH & Min, CK 2014, 'Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients', Annals of Hematology, vol. 93, no. 1, pp. 113-121. https://doi.org/10.1007/s00277-013-1893-z

Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients. / Kim, Kihyun; Kim, Seok Jin; Voelter, Verena; Suh, Cheolwon; Yoon, Sung Soo; Lee, Je Jung; Kwak, Jae Yong; Ryoo, Hun Mo; Kim, Yang Soo; Moon, Joon Ho; Park, Seong Kyu; Kim, Sung Hyun; Mun, Yeung Chul; Kim, Jinseok; Eom, Hyeon Seok; Jo, Deog Yeon; Jun, Hyun Jung; Kim, Ki Hwan; Lee, Jeong Ok; Lee, Jae Hoon; Min, Chang Ki.

In: Annals of Hematology, Vol. 93, No. 1, 01.01.2014, p. 113-121.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea - Experience from 110 patients

AU - Kim, Kihyun

AU - Kim, Seok Jin

AU - Voelter, Verena

AU - Suh, Cheolwon

AU - Yoon, Sung Soo

AU - Lee, Je Jung

AU - Kwak, Jae Yong

AU - Ryoo, Hun Mo

AU - Kim, Yang Soo

AU - Moon, Joon Ho

AU - Park, Seong Kyu

AU - Kim, Sung Hyun

AU - Mun, Yeung Chul

AU - Kim, Jinseok

AU - Eom, Hyeon Seok

AU - Jo, Deog Yeon

AU - Jun, Hyun Jung

AU - Kim, Ki Hwan

AU - Lee, Jeong Ok

AU - Lee, Jae Hoon

AU - Min, Chang Ki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.

AB - We conducted a retrospective analysis of lenalidomide with dexamethasone for patients with relapsed/refractory multiple myeloma (RRMM) who were treated within the Korean patient access program. Lenalidomide has been approved for RRMM for several years in Europe and North America, but has not been accessible to Asian patients in the past. Between 2008 and 2012, 110 patients from 20 hospitals were enrolled. The overall response rate (ORR) was 43.6 % with 15.4 % of very good partial response (VGPR) or better. The median time to progression (TTP) in this heavily pretreated patient population was 8.0 months, and median overall survival (OS) was 23 months. Hematologic toxicities, fatigue, anorexia, and constipation were the most common adverse events. The number of previous treatment lines, previous exposure to thalidomide, refractoriness to thalidomide and bortezomib, pretreatment white blood cell count (WBC), platelet count, t(14;16), and 17p deletion were significant prognostic factors for TTP, and creatinine clearance, refractoriness to thalidomide and bortezomib, performance status, platelet count, and 17p deletion were significant for OS in univariate analysis. In multivariate analysis, WBC and platelet count were significant prognostic factors for TTP and performance status for OS. For Korean myeloma patients, lenalidomide showed considerable efficacy, and toxicities were comparable to the data published in Europe and North America.

UR - http://www.scopus.com/inward/record.url?scp=84891838863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891838863&partnerID=8YFLogxK

U2 - 10.1007/s00277-013-1893-z

DO - 10.1007/s00277-013-1893-z

M3 - Article

VL - 93

SP - 113

EP - 121

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 1

ER -